It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
While classical cannabinoid receptors are known to crucially impact on myocardial infarction (MI) repair, a function of the cannabinoid-sensitive receptor GPR55 herein is poorly understood. We investigated the role of GPR55 in cardiac physiology and post-MI inflammation and remodelling. Global GPR55−/− and wildtype (WT) mice were basally characterized or assigned to 1, 3 or 28 days permanent MI and subsequently analysed via pro-inflammatory and pro-hypertrophic parameters. GPR55−/− deficiency was basally associated with bradycardia, increased diastolic LV volume and sarcomere length and a subtle inflammatory phenotype. While infarct size and myeloid cell infiltration were unaffected by GPR55 depletion, acute cardiac chemokine production was prolonged post-MI. Concurrently, GPR55−/− hearts exhibited a premature expansion of pro-reparative and phagocytic macrophages paralleled by early up-regulation of extracellular matrix (ECM) factors 3 days post-MI, which could be mimicked by sole haematopoietic GPR55 depletion. Moreover, global GPR55 deficiency mitigated MI-induced foetal gene re-programming and cardiomyocyte hypertrophy, culminating in aggravated LV dilatation and infarct expansion. GPR55 regulates cardiac homeostasis and ischaemia responses by maintaining adequate LV filling and modulating three crucial processes post-MI: wound healing kinetics, cardiomyocyte hypertrophy and maladaptive remodelling.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Ludwig-Maximilians-Universität (LMU) Munich, Institute for Cardiovascular Prevention (IPEK), Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)
2 University Clinic Würzburg, Comprehensive Heart Failure Center, Würzburg, Germany (GRID:grid.411760.5) (ISNI:0000 0001 1378 7891)
3 University Clinic Würzburg, Comprehensive Heart Failure Center, Würzburg, Germany (GRID:grid.411760.5) (ISNI:0000 0001 1378 7891); University Clinic Würzburg, Medical Clinic I, Würzburg, Germany (GRID:grid.411760.5) (ISNI:0000 0001 1378 7891)
4 Ludwig-Maximilians-Universität (LMU) Munich, Institute for Cardiovascular Prevention (IPEK), Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X); German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany (GRID:grid.452396.f) (ISNI:0000 0004 5937 5237)